Crisantaspase

Also known as: Asparaginase, Colaspase

Drug #1442

Crisantaspase is an enzyme asparaginase produced by Erwinia chrysanthemi, which acts as an anti-neoplastic agent. It breaks down the aminonacid L-asparaginase to aspartic acid and ammonia, and interferes with the growth of malignant cells, which unlike most healthy cells, are unable to synthesise L-asparaginase for their metabolism. Crisantaspase is used almost exclusively in acute lymphoblastic leukaemia.

← Previous drug Next drug →

Primary Characteristics

Crisantaspase is also known as Asparaginase, Colaspase.

It is of Natural origin and belongs to asparanginare.

Molecular Weight: 130000 · pK_a: 8.5 · Solubility in Water: readily soluble · Solubility in Alcohol: insoluble · Non-proprietary name: Crisantaspase.

Pharmacokinetics

Distribution: Crisantaspase has a volume of distribution is low.

Elimination: it is metabolised via metabolized through liver kidney, plasma half-life is 7 - 13 hr.

Indications

Crisantaspase is primarily indicated in conditions like Acute leukemia, Acute lymphocytic leukemia, Hypersensitivity of E.Coli, Lymphoblastic lymphoma, Lymphoid malgnancies, Non-hodgkin's lymphoma, Non-hodgkin's lymphoma.

Contraindications

Crisantaspase is contraindicated in conditions like Hypersensitivity, Pregnancy.

Dosage

Crisantaspase's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
20 IU/m2	20 IU/m2	—	IV	4.8hourly
Paediatric Dosage (20kg)
600 units/kg	600 units/kg	—	I/M
100	100	—	I/V	daily for 10 days after treatment with vincristine and prednisone
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Crisantaspase in overdosage may give rise to further complications which include Hepatotoxicity , Hemorrhagic pancreatitis, Hemorrhage, Hepatotoxicity , Hypermylasia, Coma , Tremors , Thrombosis , Stupor .

Crisantaspase produces potentially life-threatening effects which include Hypotension, Bronchospasm , Anaphylaxis , Bronchospasm, Laryngeal edema, Urticaria. Careful monitoring is needed with proper medical management.

Crisantaspase is known to cause more or less tolerable side effects which are usually transient. These include Abdominal distension, Abdominal pain, Confusion, Drowsiness, Fatigue, Fever, Hepatomegaly, Hyperglycemia, Increased cholestrol, Increased serum bilirubin, Malabsorption, Nausea, Vomiting .

Warnings / Precautions

Therapy should only be given where there are adequate facilities for ventilation and monitoring.

Interference in Pathology

Crisantaspase may interfere in the diagnosis of Thyroid Function Test.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

5000 KU

Multi-Ingredient Combinations

Soln

2.5 g/L

Storage Conditions

Crisantaspase should be stored Inj (reconstituted soln). Powder for Inj.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs

Manufacturers

Manufacturers of Crisantaspase in Pakistan:

S.Ejazuddin Usmanco